-

11:03:08 AM

PHAR Stock News

PHAR - Pharming Group N.V.

06/01/23 1:00 AM

Nasdaq : PHAR

Pharming announces sale of priority review voucher

Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US $21.1 million shortly after closing. Pharming was granted the PRV by the Food and...

RHEA-AI

neutral

05/25/23 2:00 AM

Nasdaq : PHAR

conferences

Pharming Group to attend the following Investor Conferences in June

Pharming Group N.V. announces that Pharming's management will attend the following investor conferences in the month of June:. Jefferies Healthcare Conference, New York, U.S., June 7- 9 Pharming's CEO, Sijmen de Vries, will present on Thursday, June 8 at 10:30 EST/ 16:30 CEST. Pharming is headquartered in Leiden,...

RHEA-AI

neutral

05/11/23 1:00 AM

Nasdaq : PHAR

earnings

Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja ® in the U.S. Joenja ® launch off to strong start with 23 U.S. patients on paid therapy Revenues decreased by 9% to US $42.5 million, compared to the first quarter of 2022, primarily due to temporary reimbursement disruptions for some patients on government insurance programs. LEIDEN, Netherlands, May 11, 2023/...

RHEA-AI

neutral

04/11/23 1:00 AM

Nasdaq : PHAR

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Pharming Group N.V. announces the first commercial shipments of Joenja ® to patients in the United States. Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja ® triggers a $10 million milestone payment by Pharming to...

RHEA-AI

very positive

03/30/23 10:37 AM

Nasdaq : PHAR

conferences

Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days

Pharming Group N.V. announces that Pharming's Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks| Genomic Medicines and Rare Disease Days, April 3- 4, 2023 in New York. Pharming's CEO and CCO will take part in a fireside chat on April 3 at...

RHEA-AI

neutral

03/24/23 2:30 PM

Nasdaq : PHAR

fda approval

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

Pharming Group N.V. announces that the US Food and Drug Administration has approved Joenja ® for the treatment of activated phosphoinositide 3- kinase delta syndrome in adult and pediatric patients 12 years...

RHEA-AI

positive

02/21/23 1:00 AM

Nasdaq, OTC : PHAR, PHGUF

clinical trial

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Pharming Group N.V./ announces that the first patient has been enrolled in its Phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3- kinase delta inhibitor, in children with activated phosphoinositide 3- kinase delta syndrome. At sites in the United...

RHEA-AI

positive

02/16/23 1:00 AM

Nasdaq : PHAR

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

Pharming Group N.V. announces that the European Medicines Agency's Committee for Human Medicinal Products has decided to shift its assessment of the Marketing Authorisation Application for leniolisib to a standard review timetable. Pharming has received the list of questions from EMA which included a request...

RHEA-AI

neutral

12/15/22 1:00 AM

Nasdaq : PHAR

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiencyInterim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase

RHEA-AI

neutral

12/07/22 1:00 AM

Nasdaq : PHAR

clinical trial

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiencyThe peer-reviewed publication heightens international understanding of APDS, a rare and recently

RHEA-AI

neutral